All news from Anaesthesiology

New Therapies For Type 1 diabetes

Researchers have identified a key target of the immune response that causes type 1 diabetes. Type 1 diabetes is an incurable autoimmune disease caused by the destruction of insulin-producing beta cells in the pancreas by immune cells called T cells.

This study, published in the journal PNAS (Proceedings of the National Academies of Sciences).

A specific type of T cell, a CD4+ T cell, recognizes a part of the beta cell (called an antigen) as foreign, initiating the immune response. Researchers have long been searching for the identity of the antigen that drives the disease.

Earlier work from A/Prof Mannering’s group showed that CD4+ T cells in the pancreas of an organ donor who had type 1 diabetes responded to a specific part of insulin’s precursor, proinsulin, known as C-peptide.

New age Health Insurance Products: Specific Customer Requirements Catered

Keeping in view the strenuous life we live, health care coverage has become a pivotal need! The increasing healthcare costs are sure to erode the financial savings, especially in a country like India where out-of-pocket medical expenses account for over 62% of the entire costs.

No doubt, the cost of healthcare is going through the roof, and there are numerous loopholes in most of the health plans being offered today. This is mostly because even a comprehensive policy fails to pay for numerous basic facilities, including pre-existing ailments, OPD cover, sub-limit, and lifetime renewability.

HIV-infected patients: Anti-Integrin Therapy Effect on Intestinal Immune System

In a study published in Science Translational Medicine, Mount Sinai researchers describe for the first time a mechanism that may shrink collections of immune cells in the gastrointestinal (GI) tract, called lymphoid aggregates, where HIV may lay sequestered. These findings may be of interest to scientists who are involved in researching the cure for HIV infection in light of the strong role that the intestines play in it.

Clinical Trials Offers a Promising Treatment Against PKDL

A clinical trial to find a better treatment for severe or chronic cases of post kala-azar dermal leishmaniasis (PKDL) in Africa has begun in Dooka, Sudan. The objective of this clinical trial, which is being conducted by the Drugs for Neglected Diseases initiative (DNDi), a non-profit research and development organization, and the Institute for Endemic Diseases (IEND) at the University of Khartoum, is to shorten the length of hospitalization for PKDL and deliver a treatment that is safer to use and easier to administer.

New Algorithm: Antibiotic Candidates Found Efficiently

Researchers describe a new means of searching vast repositories of compounds produced by microbes. By analyzing the mass spectra of the compounds, they were able to identify known compounds within the repository and eliminate them from further analysis, focusing instead on the unknown variants that might potentially be better or more efficient antibiotics, anticancer drugs or other pharmaceuticals.

Vaccine Research Against Cryptosporidium, New Study

In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. The culprit in nine out of ten cases in which an infectious cause was identified was the microscopic parasite Cryptosporidium.